These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 34897833)

  • 1. Incidence and mortality of post-transplant lymphoproliferative disorders after kidney transplantation: A real-world retrospective analysis in Japan.
    Kato T; Yoshida T; Taniguchi A; Kawamura M; Nakazawa S; Namba-Hamano T; Yamanaka K; Abe T; Kishikawa H; Nonomura N; Imamura R
    Int J Urol; 2022 Mar; 29(3):206-211. PubMed ID: 34897833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-Transplant Lymphoproliferative Disorder in Kidney Transplant Recipients: A Single-Center Experience in Japan.
    Ishihara H; Shimizu T; Unagami K; Hirai T; Toki D; Omoto K; Okumi M; Imai Y; Ishida H; Tanabe K
    Ther Apher Dial; 2016 Apr; 20(2):165-73. PubMed ID: 26948427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low 5-year cumulative incidence of post-transplant lymphoproliferative disorders after solid organ transplantation in Switzerland.
    Steiner R; Kridel R; Giostra E; McKee T; Achermann R; Mueller N; Manuel O; Dickenmann M; Schuurmans MM; de Leval L; Fehr T; Tinguely M; Binet I; Cogliatti S; Haralamvieva E; Koller M; The Swiss Transplant Cohort Study Stcs ; Dietrich PY
    Swiss Med Wkly; 2018; 148():w14596. PubMed ID: 29518251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-transplantation lymphoproliferative disorder in heart and kidney transplant patients: a single-center experience.
    Wasson S; Zafar MN; Best J; Reddy HK
    J Cardiovasc Pharmacol Ther; 2006 Mar; 11(1):77-83. PubMed ID: 16703222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A French Cohort Study of Kidney Retransplantation after Post-Transplant Lymphoproliferative Disorders.
    Caillard S; Cellot E; Dantal J; Thaunat O; Provot F; Janbon B; Buchler M; Anglicheau D; Merville P; Lang P; Frimat L; Colosio C; Alamartine E; Kamar N; Heng AE; Durrbach A; Moal V; Rivalan J; Etienne I; Peraldi MN; Moreau A; Moulin B;
    Clin J Am Soc Nephrol; 2017 Oct; 12(10):1663-1670. PubMed ID: 28818847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Posttransplant Lymphoproliferative Disorder in Adults Receiving Kidney Transplantation in British Columbia: A Retrospective Cohort Analysis.
    Ready E; Chernushkin K; Partovi N; Hussaini T; Luo C; Johnston O; Shapiro RJ
    Can J Kidney Health Dis; 2018; 5():2054358118760831. PubMed ID: 29636980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Post-transplantation lymphoproliferative disorder in childhood].
    Stréhn A; Szőnyi L; Kriván G; Kovács L; Reusz G; Szabó A; Rényi I; Kovács G; Dezsőfi A
    Orv Hetil; 2014 Feb; 155(8):313-8. PubMed ID: 24534879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Posttransplant lymphoproliferative disorder after liver and kidney transplant.
    Akar Özkan E; Özdemir BH; Deniz EE; Tunca MZ; Haberal M
    Exp Clin Transplant; 2014 Mar; 12 Suppl 1():142-8. PubMed ID: 24635813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors for early-onset and late-onset post-transplant lymphoproliferative disorder in kidney recipients in the United States.
    Quinlan SC; Pfeiffer RM; Morton LM; Engels EA
    Am J Hematol; 2011 Feb; 86(2):206-9. PubMed ID: 21264909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-transplant lymphoproliferative disorder following kidney transplantation: a population-based cohort study.
    Maksten EF; Vase MØ; Kampmann J; d'Amore F; Møller MB; Strandhave C; Bendix K; Bistrup C; Thiesson HC; Søndergaard E; Hamilton-Dutoit S; Jespersen B
    Transpl Int; 2016 Apr; 29(4):483-93. PubMed ID: 26749337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-renal transplant malignancies: Opportunities for prevention and early screening.
    Turshudzhyan A
    Cancer Treat Res Commun; 2021; 26():100283. PubMed ID: 33338850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Posttransplant Lymphoproliferative Disorders in Irish Renal Transplant Recipients: Insights From a National Observational Study.
    OʼRegan JA; Prendeville S; McCaughan JA; Traynor C; OʼBrien FJ; Ward FL; OʼDonovan D; Kennedy C; Berzan E; Kinsella S; Williams Y; OʼKelly P; Deady S; Comber H; Leader M; Conlon PJ
    Transplantation; 2017 Mar; 101(3):657-663. PubMed ID: 27214265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-transplant lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment.
    Muti G; Cantoni S; Oreste P; Klersy C; Gini G; Rossi V; D'Avanzo G; Comoli P; Baldanti F; Montillo M; Nosari A; Morra E;
    Haematologica; 2002 Jan; 87(1):67-77. PubMed ID: 11801467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients.
    Swinnen LJ; Costanzo-Nordin MR; Fisher SG; O'Sullivan EJ; Johnson MR; Heroux AL; Dizikes GJ; Pifarre R; Fisher RI
    N Engl J Med; 1990 Dec; 323(25):1723-8. PubMed ID: 2100991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary Epstein-Barr virus infection, seroconversion, and post-transplant lymphoproliferative disorder in seronegative renal allograft recipients: a prospective cohort study.
    Hosseini-Moghaddam SM; Alhomayeed B; Soliman N; Weir MA; House AA
    Transpl Infect Dis; 2016 Jun; 18(3):423-30. PubMed ID: 27016725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence and predictors of post-transplant lymphoproliferative disease after kidney transplantation during adulthood and childhood: a registry study.
    Francis A; Johnson DW; Teixeira-Pinto A; Craig JC; Wong G
    Nephrol Dial Transplant; 2018 May; 33(5):881-889. PubMed ID: 29342279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations.
    Walker RC; Paya CV; Marshall WF; Strickler JG; Wiesner RH; Velosa JA; Habermann TM; Daly RC; McGregor CG
    J Heart Lung Transplant; 1995; 14(2):214-21. PubMed ID: 7779838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. No Increased Risk of Posttransplant Lymphoproliferative Disorder Following Alemtuzumab Induction in Kidney Transplant.
    Oliver M; Mitro G; Tenbrink P; Alharthi S; Bedford N; Wu J; Gohara A; Jordan M; Zaremba C; Rees M; Ortiz J
    Exp Clin Transplant; 2019 Jun; 17(3):320-325. PubMed ID: 29363415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-transplant lymphoproliferative disease in heart and lung transplantation: Defining risk and prognostic factors.
    Kumarasinghe G; Lavee O; Parker A; Nivison-Smith I; Milliken S; Dodds A; Joseph J; Fay K; Ma DD; Malouf M; Plit M; Havryk A; Keogh AM; Hayward CS; Kotlyar E; Jabbour A; Glanville AR; Macdonald PS; Moore JJ
    J Heart Lung Transplant; 2015 Nov; 34(11):1406-14. PubMed ID: 26279197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different causes of early and late-onset post transplant lymphoproliferative disorder in kidney transplantation patients after 2000.
    Gwon JG; Kim YH; Han DJ
    Asian J Surg; 2019 Apr; 42(4):551-556. PubMed ID: 30327178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.